Longitudinal analysis of mutational variant allele frequencies, proportions of CD123+ blasts, expression patterns of CD123 blasts and proportions of monocyte subsets in CMML patients enrolled on the clinical trial. (A) Frequency of BMA blasts and VAF of specific gene mutations associated with CMML in 5 patients receiving tagraxofusp 12 μg/kg over 4 treatment cycles. (B) Median (represented by solid line) frequency of CD123⁺ blasts assessed by flow cytometry in the PB and BMAs of 13 patients with CMML receiving tagraxofusp 12 μg/kg per day. (C) Relative expression of CD123 on the surface of blasts in the PB during treatment (line represents median, n = 13). (D) Frequency of monocyte subsets (MO1 and MO3 monocytes) over the course of treatment (solid line represents median, n = 13). BMA, BM aspirate; C1D1, cycle 1, day 1; PB, peripheral blood; VAF, variant allele frequency.